Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines

Shen,Bin; Dong,Pin; Li,Dawei; Gao,Shang

doi:10.3892/etm.2011.331

Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines

Authors:
- Bin Shen
- Pin Dong
- Dawei Li
- Shang Gao
View Affiliations

Affiliations: Department of Otolaryngology - Head and Neck Surgery, Shanghai Jiaotong University Affiliated First People's Hospital, Shanghai 200080, P.R. China
Published online on: August 11, 2011 https://doi.org/10.3892/etm.2011.331
Pages: 1151-1157

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Overexpression of breast cancer resistance protein, the ATP-binding cassette, subfamily G, member2 (BCRP/ABCG2), confers multidrug resistance to tumor cells and often limits the efficacy of chemotherapy. The aim of this study was to investigate the expression and functional activity of ABCG2 in head and neck squamous cell carcinoma (HNSCC) and corresponding cell lines. Immunohistochemistry was performed to investigate the presence of the ABCG2 transporter in HNSCC tissues. Expression of ABCG2 in the Hep-2, Hep-2T, CNE and FaDu cell lines was analyzed by real-time quantitative reverse transcription-polymerase chain reaction and Western blotting at the levels of messenger RNA (mRNA) and protein, respectively. The drug sensitivity of the above four cell lines to mitoxantrone was detected using MTT, and the drug accumulation of mitoxantrone was analyzed by flow cytometry. Positive expression of ABCG2 was detected in 52.04% of the laryngeal cancer samples from 98 patients, in 65% of the 40 hypopharyngeal cancer samples and in 58.82% of the 34 nasopharyngeal cancer samples. The level of expression was found to be correlated with tumor TNM stage (P<0.05) and lymph node metastasis (P<0.01). All four HNSCC cell lines expressed ABCG2 at the mRNA and protein levels. The levels of ABCG2 expression in the four cell lines were significantly correlated with the function and sensitivity to mitoxantrone. The addition of fumitremorgin C at a concentration of 5 µM to mitoxantrone treatment caused a varied increase in mitoxantrone accumulation of 1.09-fold, 1.33-fold (P<0.01), 1.4-fold (P<0.01) and 1-fold in the Hep-2, Hep-2T, CNE and FaDu cells, respectively. Expression of ABCG2 varied among the different types of carcinoma tissues and each HNSCC cell line, and it induced multidrug resistance and separation of cancer stem cells attributing to its efflux pump function. Thus, ABCG2 expression may be an unfavorable prognostic factor for HNSCC. Due to the negligible expression and function of ABCG2, we suggest that the FaDu cell line is suitable to be a negative control in studies involving HNSCC. Taken together, ABCG2 is a promising universal biomarker of cancer stem cells and a target gene for HNSCC chemotherapy.

View Figures

View References

1	Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer statistics, 2000. CA Cancer J Clin. 50:7–33. 2000. View Article : Google Scholar
2	Vokes EE, Weichselbaum RR, Lippman SM and Hong WK: Head and neck cancer. N Engl J Med. 328:184–194. 1993. View Article : Google Scholar : PubMed/NCBI
3	Clark JI, Hofmeister C, Choudhury A, et al: Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. Cancer. 92:2334–2340. 2001. View Article : Google Scholar : PubMed/NCBI
4	Dean M, Hamon Y and Chimini G: The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res. 42:1007–1017. 2001.PubMed/NCBI
5	Ross DD and Nakanishi T: Impact of breast cancer resistance protein on cancer treatment outcomes. Methods Mol Biol. 596:251–290. 2010. View Article : Google Scholar : PubMed/NCBI
6	Doyle LA, Yang W, Abruzzo LV, et al: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 95:15665–15670. 1998. View Article : Google Scholar : PubMed/NCBI
7	Diestra JE, Condom E, del Muro XG, et al: Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance-related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications. J Urol. 170:1383–1387. 2003.
8	Sauerbrey A, Sell W, Steinbach D, Voigt A and Zintl F: Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia. Br J Haematol. 118:147–150. 2002. View Article : Google Scholar : PubMed/NCBI
9	Abbott BL, Colapietro AM, Barnes Y, Marini F, Andreeff M and Sorrentino BP: Low levels of ABCG2 expression in adult AML blast samples. Blood. 100:4594–4601. 2002. View Article : Google Scholar : PubMed/NCBI
10	Plasschaert SL, van der Kolk DM, de Bont ES, et al: The role of breast cancer resistance protein in acute lymphoblastic leukemia. Clin Cancer Res. 9:5171–5177. 2003.PubMed/NCBI
11	Benderra Z, Faussat AM, Sayada L, et al: Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res. 10:7896–7902. 2004. View Article : Google Scholar : PubMed/NCBI
12	Nakayama K, Kanzaki A, Ogawa K, Miyazaki K, Neamati N and Takebayashi Y: Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin-based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. Int J Cancer. 101:488–495. 2002. View Article : Google Scholar
13	Faneyte IF, Kristel PM, Maliepaard M, et al: Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res. 8:1068–1074. 2002.PubMed/NCBI
14	Tsunoda S, Okumura T, Ito T, et al: ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma. Oncology. 71:251–258. 2007. View Article : Google Scholar : PubMed/NCBI
15	Yoh K, Ishii G, Yokose T, et al: Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res. 10:1691–1697. 2004. View Article : Google Scholar : PubMed/NCBI
16	Jin Y, Bin ZQ, Qiang H, et al: ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. J Cancer Res Clin Oncol. 135:1369–1376. 2009. View Article : Google Scholar : PubMed/NCBI
17	Polgar O, Robey RW and Bates SE: ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol. 4:1–15. 2008. View Article : Google Scholar : PubMed/NCBI
18	Honjo Y, Hrycyna CA, Yan QW, et al: Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res. 61:6635–6639. 2001.PubMed/NCBI
19	Robey RW, Honjo Y, Morisaki K, et al: Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer. 89:1971–1978. 2003. View Article : Google Scholar : PubMed/NCBI
20	Ejendal KFK, Diop NK, Schweiger LC and Hrycyna CA: The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding. Protein Sci. 15:1597–1607. 2006. View Article : Google Scholar : PubMed/NCBI
21	Miwa M, Tsukahara S, Ishikawa E, Asada S, Imai Y and Sugimoto Y: Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants. Int J Cancer. 107:757–763. 2003. View Article : Google Scholar
22	Song J, Chang I, Chen Z, Kang M and Wang CY: Characterization of side populations in HNSCC: highly invasive, chemoresistant and abnormal Wnt signaling. PloS One. 5:e114562010. View Article : Google Scholar : PubMed/NCBI
23	Schwabedissen HE and Kroemer HK: In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb Exp Pharmacol. 201:325–371. 2011. View Article : Google Scholar : PubMed/NCBI
24	Li L, Jiang AC, Dong P, Wan Y and Yu ZW: The characteristics of Hep-2 cells with multiple drug resistance induced by Taxol. Otolaryngol Head Neck Surg. 137:659–664. 2007. View Article : Google Scholar : PubMed/NCBI
25	Allen JD, van Loevezijn A, Lakhai JM, et al: Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther. 1:417–425. 2002.
26	Robey RW, To KK, Polgar O, et al: ABCG2: a perspective. Adv Drug Deliv Rev. 61:3–13. 2009. View Article : Google Scholar
27	Benderra Z, Faussat AM, Sayada L, et al: MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res. 11:7764–7772. 2005. View Article : Google Scholar : PubMed/NCBI
28	Uggla B, Stahl E, Wagsater D, et al: BCRP mRNA expression v. clinical outcome in 40 adult AML patients. Leuk Res. 29:141–146. 2005. View Article : Google Scholar : PubMed/NCBI
29	Suvannasankha A, Minderman H, O'Loughlin KL, et al: Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function. Leukemia. 18:1252–1257. 2004. View Article : Google Scholar : PubMed/NCBI
30	Sawyers CL: The cancer biomarker problem. Nature. 452:548–552. 2008. View Article : Google Scholar : PubMed/NCBI
31	Maliepaard M, Scheffer GL, Faneyte IF, et al: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61:3458–3464. 2001.PubMed/NCBI
32	Young LC, Campling BG, Cole SPC, Deeley RG and Gerlach JH: Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res. 7:1798–1804. 2001.PubMed/NCBI
33	Hirschmann-Jax C, Foster AE, Wulf GG, et al: A distinct ‘side population’ of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 101:14228–14233. 2004.
34	Haraguchi N, Utsunomiya T, Inoue H, et al: Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells. 24:506–513. 2006. View Article : Google Scholar : PubMed/NCBI